Home>>Signaling Pathways>> Microbiology & Virology>> HIV>>2',3'-Dideoxyadenosine

2',3'-Dideoxyadenosine (Synonyms: ddA, ddAdo, NSC 98700)

Catalog No.GC33994

2',3'-Dideoxyadenosine is an inhibitor of HIV replication.

Products are for research use only. Not for human use. We do not sell to patients.

2',3'-Dideoxyadenosine Chemical Structure

Cas No.: 4097-22-7

Size Price Stock Qty
10mg
$73.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

2',3'-Dideoxyadenosine is an inhibitor of HIV replication[1]. Antiretroviral activity[1]. Antiviral efficacy[1].

2',3'-Dideoxyadenosine inhibits HIV-1 and simian immunodeficiency virus (SIV) in MT-4 cells with EC50s of 5.27 and 5.3 μM, respectively. 2',3'-Dideoxyadenosine inhibits HIV-1 and HIV-2 in human T-lymphocyte CEM cells with EC50s of 4 μM and 8 μM, respectively. 2',3'-Dideoxyadenosine inhibits HIV-1 and HIV-2 in Molt 4/C8 cells with EC50s of 4 μM and 5.5 μM, respectively. 2',3'-Dideoxyadenosine inhibits HIV-1 and HIV-2 in C8166 cells with EC50s of 17 μM and 22 μM, respectively. 2',3'-Dideoxyadenosine inhibits murine sarcoma virus (MSV) in C3H/3T3 cells with an EC50 of 24 μM[1].

[1]. Balzarini J, et al. Conversion of 2',3'-dideoxyadenosine (ddA) and 2',3'-didehydro-2',3'-dideoxyadenosine (d4A) to their corresponding aryloxyphosphoramidate derivatives markedly potentiates their activity against human immunodeficiency virus and hepatitis B virus. FEBS Lett. 1997 Jun 30;410(2-3):324-8.

Reviews

Review for 2',3'-Dideoxyadenosine

Average Rating: 5 ★★★★★ (Based on Reviews and 23 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 2',3'-Dideoxyadenosine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.